Phaseline

Targets › DPYD

DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]): drug programs, companies and trials

4 programs from 4 companies in 5 trials: 3 Phase 2, 2 Phase 3; Oncology; next expected readout Dec 2026.

Catalyzes the reduction of uracil and thymine in the initial step of reductive pyrimidine catabolism, a pathway that yields beta-alanine from uracil and beta-aminoisobutyrate from thymine. Also capable of degrading the chemotherapeutic drug 5-fluorouracil. (UniProt, Q12882)

Open in Phaseline: the race on DPYD, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kyungpook National University HospitalFOLFOX-6
Combination chemotherapy: oxaliplatin (platinum agent), leucovorin (reduced folate), and 5
DPYD, TYMS, DHFRPhase 3Colon CancerDec 2026
National Cancer Center Hospital EastCAPOXIRI
Combination chemotherapy: capecitabine (5-FU prodrug), oxaliplatin (platinum agent), and i
DPYD, TOPO1, XRCC1Phase 3Locally Advanced Rectal CancerDec 2029
Fudan UniversitymFOLFIRINOX plus IMRT
Multi-drug chemotherapy regimen (5-fluorouracil, folinic acid, irinotecan, oxaliplatin) co
TOPO1, DPYD, TYMS, DHFRPhase 2Pancreatic Adenocarcinoma; Pancreatic CancerMar 2028
Processa PharmaceuticalsEniluracil (PCS6422)
Dihydropyrimidine dehydrogenase inhibitor
DPYDPhase 2Breast Cancer–

Conditions

Locally Advanced Rectal Cancer (1) Pancreatic Adenocarcinoma (1) Pancreatic Cancer (1) Colon Cancer (1) Breast Cancer (1)

Modalities

small molecule (3)

Companies

National Cancer Center Hospital East (1) Fudan University (1) Kyungpook National University Hospital (1) Processa Pharmaceuticals (1)

Related targets

TOPO1 (2) TYMS (2) DHFR (2) XRCC1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.